Recognizing the dynamic nature of the psychiatry therapeutic arena, a top-5 pharmaceutical company required support in characterizing and prioritizing the stakeholder environment to inform how Medical Affairs could work with other functions to optimize patient care.
A global pharmaceutical company wanted to identify diagnostic technologies that would support the clinical development and commercial performance of agents targeting two infectious diseases and represent potential partnership opportunities.
A leading pharmaceutical company required support in identifying and planning for risks and scenarios that could arise during a multinational Phase 3 vaccine clinical trial.
Shift Health was engaged by a leading US investment firm to evaluate an asset and project sales in order to inform their decision to invest in an established biotechnology company expanding into new markets.
A multinational pharmaceutical company sought support to engage with haemophilia A individuals and caregivers to gather firsthand perspectives on the impact of current and value of future therapies.